Biotech Essentials

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 29.06.2021.

#LongCovid
#microrna
#businessdevelopment
#SupervisoryBoardMembers
#NOXXON
#finance
#clinical
#IPF
#heartfailure
#hypertrophy

Healthcare

@jonathanrockoff shared
On Jun 23, 2021
RT @matthewherper: Peter Bach, industry critic and biotwitter's @peterbachmd, is becoming Chief Medical Officer of Delfi Diagnostics, a company aiming to make blood tests to detect cancer. https://t.co/FoKWuUC8w7
Open
Peter Bach, industry critic, joins company aiming to make blood tests to detect cancer

Peter Bach, industry critic, joins company aiming to make blood tests to detect cancer

The director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes will become the chief medical officer of Delfi Diagnostics.

@BIODeutschland shared
On Jun 25, 2021
RT @noxxon_pharma: Meet #NOXXON’s new #SupervisoryBoardMembers: Susan Coles @Vivet_tx, Martine van Vugt @Genmab & Greg Weaver @atai_life. Their expertise in #lifesci, #finance, #clinical & #businessdevelopment will help NOXXON navigate its transformational period. Full bios: https://t.co/hvFHBPDDaS https://t.co/DT6X0MkZRD
Open
Supervisory Board

Supervisory Board

Prior to co-founding Kreos, Maurizio was managing partner of PMA Europe, London, a consulting partnership focused on assisting private equity firms and corporate clients in …

@BIODeutschland shared
On Jun 28, 2021
RT @PierisPharma: Proud to announce the development of PRS-220, an oral inhaled Anticalin protein targeting CTGF, for the treatment of #IPF. We have also been selected to receive a ~$17M grant from the Bavarian gov't to evaluate PRS-220 for #LongCovid! https://t.co/KwsuC4Q89b https://t.co/3dhYhP2z2X
Open
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic …

@jonathanrockoff shared
On Jun 23, 2021
RT @EricTopol: Just published @NatureMedicine A prospective cohort with #LongCovid, mostly initially with mild illness, but at 6 months majority had debilitating symptoms, including breathing and cognitive difficulties. Higher neutralizing antibodies notable. https://t.co/zEIPn0Vc6k https://t.co/KHr25Jz761
Open
Long COVID in a prospective cohort of home-isolated patients

Long COVID in a prospective cohort of home-isolated patients

Analysis of a prospectively enrolled cohort of patients with SARS-CoV-2 infections in Bergen, Norway, reveals a high proportion of patients who experienced long COVID symptoms at 6 months, ...

@matthewherper shared
On Jun 24, 2021
RT @HollyLynchez: H/t to @ABatemanHouse Someone please tell me that using patients “as their own control” (as proposed in this article) is not really on the table. Biogen, fresh off coveted FDA nod for Aduhelm, must now navigate ethics minefield for phase 4 trial https://t.co/dGbeyaZnWp
Open
Biogen, fresh off coveted FDA nod for Aduhelm, must now navigate ethics minefield for phase 4 trial

Biogen, fresh off coveted FDA nod for Aduhelm, must now navigate ethics minefield for phase 4 trial

After the Aduhelm approval set a precedent for FDA clearance based on surrogate endpoints, all eyes will be on Biogen as it conducts a trial in the post-approval environment. The biotech, ...

@Biotechnology shared
On Jun 29, 2021
UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body https://t.co/iHPKInoc3Q https://t.co/UozbH0PfdR
Open
UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body

UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body

Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing ...

@BIODeutschland shared
On Jun 24, 2021
RT @akampion: Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart: https://t.co/HPZbW06XjF #cardiovascular #cardiology #heartfailure #microrna #hypertrophy
Open
Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart

Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart

— First-ever data on therapeutic miR-132 inhibition in a large animal model of nonischemic heart failure with cardiac hypertrophy and fibrosis — Peer-reviewed publication in the …

@healthythinker shared
On Jun 24, 2021
The #COVID19 #pandemic re-shaping global economy & microeconomics of #healthcare for each country, & #healthcitizens https://t.co/vcae91JJRq @FitchSolutions research on #endemic virus, #vaccines #PublicHealth #healthcosts Important link to "How Epidemics End" @EricaCharters https://t.co/tgnH9c844H
Open
The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

Getting totally rid of the coronavirus isn’t likely, so we humans must accept the fact that SARS-CoV-2 will be endemic. The economic and healthcare system impacts of this were explored in ...